TELA Bio (NASDAQ:TELA - Get Free Report) is projected to post its quarterly earnings results after the market closes on Thursday, March 20th. Analysts expect TELA Bio to post earnings of ($0.24) per share and revenue of $23.17 million for the quarter. Individual that wish to listen to the company's earnings conference call can do so using this link.
TELA Bio Price Performance
NASDAQ TELA opened at $2.27 on Thursday. The stock's 50-day moving average price is $2.65 and its two-hundred day moving average price is $2.74. The company has a current ratio of 2.62, a quick ratio of 1.81 and a debt-to-equity ratio of 14.22. The company has a market cap of $89.41 million, a PE ratio of -1.34 and a beta of 1.10. TELA Bio has a 1 year low of $2.24 and a 1 year high of $6.50.
About TELA Bio
(
Get Free Report)
TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider TELA Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TELA Bio wasn't on the list.
While TELA Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
